← Back to Search

1 year follow-up for Cardiovascular Disease (CASCADE Trial)

N/A
Recruiting
Led By Joerg Herrmann, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

CASCADE Trial Summary

This trial is designed to improve cardiovascular care for adult cancer survivors. The goal is to gather data to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.

Eligible Conditions
  • Cardiovascular Disease
  • Cancer

CASCADE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Diagnostic performance of AI-ECG and NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%
Diagnostic performance of AI-ECG for left ventricular ejection fraction (LVEF) < 50%
Diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%
Secondary outcome measures
Absolute change in AI-ECG probability for LVEF <50% from baseline to 1 year from anthracycline-based therapy
Absolute change in LVEF from baseline to 1 year from anthracycline-based therapy
Absolute change in NT-pro-BNP from baseline to 1 year from anthracycline-based therapy
+2 more

CASCADE Trial Design

2Treatment groups
Experimental Treatment
Group I: Prior to anthracycline-based therapyExperimental Treatment3 Interventions
patients presenting before the start of anthracycline-based therapy, then to be followed thereafter for 1 year and thereby contributing to the pool of patients with 1-year post-anthracycline assessment.
Group II: 1 year follow-upExperimental Treatment3 Interventions
patients who were treated in the year before and are now returning for their 1-year follow-up.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Electrocardiogram
2014
Completed Phase 2
~3060
Echocardiogram
2016
Completed Phase 2
~1000

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,176 Previous Clinical Trials
3,757,851 Total Patients Enrolled
Miami Heart Research InstituteUNKNOWN
1 Previous Clinical Trials
450 Total Patients Enrolled
Joerg Herrmann, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor presently recruiting participants?

"At this time, the information hosted on clinicaltrials.gov reveals that recruitment for this trial is still taking place. The original posting was March 3rd 2022 and it has been reviewed as recently as November 15th of the same year."

Answered by AI

What are the principal goals of this experiment?

"This clinical trial will be evaluating the diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%, over a 1 year post anthracycline therapy period. Secondary outcomes include assessing absolute change in LVEF and NT-pro BNP from baseline to one year after starting treatment, as well as determining any correlations between changes in these two variables."

Answered by AI

How much support has this experiment gained from the public?

"Affirmative. Information hosted on clinicaltrials.gov corroborates that this medical trial, which was inaugurated on March 3rd 2022, is actively seeking participants. Around 200 individuals must be enrolled from a single research facility for the study to continue."

Answered by AI

Are individuals under the age of 30 being accepted into this research initiative?

"The criteria for participation in this medical trial states that applicants must be 18 years or older, but cannot exceed the age of 99."

Answered by AI

Are there any qualifications for participating in this trial?

"To qualify for this clinical trial, applicants must be between 18 and 99 years of age with a pre-existing cardiovascular condition. Additionally, they need to have been diagnosed breast cancer, lymphoma or sarcoma; plus they must either be currently undergoing or one year post completion of anthracycline therapy."

Answered by AI
~45 spots leftby Oct 2024